Citations (17)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Thomas Müller. (2017) Current and investigational non-dopaminergic agents for management of motor symptoms (including motor complications) in Parkinson’s disease. Expert Opinion on Pharmacotherapy 18:14, pages 1457-1465.
Read now
Read now
Thomas Müller. (2016) Emerging approaches in Parkinson’s disease – adjunctive role of safinamide. Therapeutics and Clinical Risk Management 12, pages 1151-1160.
Read now
Read now
F. Javier Álvarez. (2016) Parkinson’s disease, antiparkinson medicines, and driving. Expert Review of Neurotherapeutics 16:9, pages 1023-1032.
Read now
Read now
Cornelis J Van der Schyf. (2015) Rational drug discovery design approaches for treating Parkinson’s disease. Expert Opinion on Drug Discovery 10:7, pages 713-741.
Read now
Read now
Livia Dézsi & László Vécsei. (2014)
Safinamide for the treatment of Parkinson's disease. Expert Opinion on Investigational Drugs 23:5, pages 729-742.
Read now
Read now
Articles from other publishers (12)
Thomas Müller. 2022. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy
2853
2870
.
Della G.T. Parambi. (2020) Treatment of Parkinson’s Disease by MAO-B Inhibitors, New Therapies and Future Challenges - A Mini-Review. Combinatorial Chemistry & High Throughput Screening 23:9, pages 847-861.
Crossref
Crossref
Thomas Müller. 2019. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy
1
18
.
Fábio G. Teixeira, Miguel F. Gago, Paulo Marques, Pedro Silva Moreira, Ricardo Magalhães, Nuno Sousa & António J. Salgado. (2018) Safinamide: a new hope for Parkinson’s disease?. Drug Discovery Today 23:3, pages 736-744.
Crossref
Crossref
Andrew C. Flick, Hong X. Ding, Carolyn A. Leverett, Robert E. KyneJr.Jr., Kevin K. -C. Liu, Sarah J. Fink & Christopher J. O’Donnell. (2017) Synthetic Approaches to the New Drugs Approved During 2015. Journal of Medicinal Chemistry 60:15, pages 6480-6515.
Crossref
Crossref
Min-Ho Nam, Moosung Park, Hyeri Park, Youngjae Kim, Seulki Yoon, Vikram Shahaji Sawant, Ji Won Choi, Jong-Hyun Park, Ki Duk Park, Sun-Joon Min, C. Justin Lee & Hyunah Choo. (2017) Indole-Substituted Benzothiazoles and Benzoxazoles as Selective and Reversible MAO-B Inhibitors for Treatment of Parkinson’s Disease. ACS Chemical Neuroscience 8:7, pages 1519-1529.
Crossref
Crossref
Md Zeeshan Rasheed, Heena Tabassum & Suhel Parvez. (2016) Mitochondrial permeability transition pore: a promising target for the treatment of Parkinson’s disease. Protoplasma 254:1, pages 33-42.
Crossref
Crossref
Thomas Müller. (2016) Nondopaminergic therapy of motor and nonmotor symptoms in Parkinson's disease: a clinician's perspective. Neurodegenerative Disease Management 6:5, pages 385-398.
Crossref
Crossref
Simona Distinto, Rita Meleddu, Matilde Yanez, Roberto Cirilli, Giulia Bianco, Maria Luisa Sanna, Antonella Arridu, Pietro Cossu, Filippo Cottiglia, Cristina Faggi, Francesco Ortuso, Stefano Alcaro & Elias Maccioni. (2016) Drug design, synthesis, in vitro and in silico evaluation of selective monoaminoxidase B inhibitors based on 3-acetyl-2-dichlorophenyl-5-aryl-2,3-dihydro-1,3,4-oxadiazole chemical scaffold. European Journal of Medicinal Chemistry 108, pages 542-552.
Crossref
Crossref
Yonghwang Ha, Jeong A Jeong, Youngsam Kim & David G. Churchill. 2016. The Alkali Metal Ions: Their Role for Life. The Alkali Metal Ions: Their Role for Life
585
601
.
Carlo Cattaneo, R. La Ferla, Erminio Bonizzoni & Marco Sardina. (2015) Long-Term Effects of Safinamide on Dyskinesia in Mid- to Late-Stage Parkinson’s Disease: A Post-Hoc Analysis. Journal of Parkinson's Disease 5:3, pages 475-481.
Crossref
Crossref
Matthias D. Mertens, Sonja Hinz, Christa E. Müller & Michael Gütschow. (2014) Alkynyl–coumarinyl ethers as MAO-B inhibitors. Bioorganic & Medicinal Chemistry 22:6, pages 1916-1928.
Crossref
Crossref